News | Blood Testing | January 04, 2017

Blood Test Predicts Silent Heart Disease Risk

Study shows that blood troponin levels can predict risk of heart attack and death, and response to statins

troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF

January 4, 2017 — A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new research funded by the British Heart Foundation (BHF).

The study, published in the Journal of the American College of Cardiology, shows the troponin test – currently used to help diagnose a heart attack - could also be a more effective way of assessing future heart disease risk than blood pressure or cholesterol. 

As a result, the researchers say the test could more precisely identify people who will benefit from statins, and assess the impact that statins are having in lowering someone’s heart disease risk.

Coronary heart disease — the cause of heart attacks — is the United Kingdom’s single biggest killer, accounting for nearly 70,000 deaths in the U.K. each year. When heart muscle is damaged it leaks a protein called troponin into the blood stream. Patients suspected of suffering a heart attack will often be given a troponin test to aide diagnosis, but until now the test has not been used to assess future heart attack risk. 

In this study of over 3,000 men with high cholesterol but no history of heart disease, the team found that changes in blood levels of a high-sensitivity troponin test from Abbott Diagnostics accurately predicted the risk of a person suffering a heart attack or dying of coronary heart disease up to 15 years later.

Troponin improved the prediction of coronary heart disease risk, adding to traditional markers such as cholesterol levels and blood pressure. If borne out in larger, more diverse studies, doctors may be able to use the troponin test to determine which patients are most likely to develop coronary heart disease.

The researchers from the University of Edinburgh and University of Glasgow also found that by measuring levels of troponin in the blood they could tell which patients were responding to the statins used to treat them.

Remarkably, taking a statin reduced troponin levels. Those whose troponin levels decreased the most had a five-fold lower risk of heart attack or death from coronary heart disease compared with those who troponin levels were unchanged or increased. A decrease in troponin could indicate treatment is effective, whereas any increases in blood troponin could prompt a change in treatment strategy.

Statins are used to prevent coronary heart disease in people who are considered high-risk, but more accurate risk assessment could help doctors target treatment to those who need it most. Statins are currently recommended for patients considered at high risk of cardiovascular disease based on traditional clinical indicators. Higher levels of troponin may reflect “silent” coronary artery disease, and identify those at greatest risk who could benefit from targeted therapy.

While encouraging, these results were obtained in a population of middle-aged men with high blood cholesterol. Further work to see whether the same effects are seen in women and men with lower cholesterol levels will need to take place before the test can be used in clinical practice.

Prof. Nicholas Mills, BHF senior clinical research fellow at the University of Edinburgh, who led the research, said, “These results are tremendously exciting, and could revolutionize the way we manage patients at risk of coronary heart disease.

“Whilst blood cholesterol levels and blood pressure are important and associated with the risk of developing heart disease, troponin is a direct measure of injury to the heart. Troponin testing will help doctors to identify apparently healthy individuals who have silent heart disease so we can target preventative treatments to those who are likely to benefit most.”

For more information: www.onlinejacc.org

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing| March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Frost & Sullivan, biomarkers, cardiac disease diagnosis, analysis
News | Blood Testing| January 12, 2016
Even though brain natriuretic peptide (BNP)/pro-BNP and troponin biomarkers are the gold standard for cardiac disease...
Overlay Init